Haitian Creole
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
1 3 glucan/kansè
Lyen an sove nan clipboard la
Paj 1 soti nan 41 rezilta yo
Radiolabeled glucans which bind to leukocytes, sites of infection, inflammation, atherosclerosis, or cancer
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to radiodiagnostic agents and reagents for preparing such agents, and also methods for producing radiolabeled radiodiagnostic agents. Specifically, the invention relates to technetium-99m (.sup.99m Tc) labeled agents,
Treatment of tumors with glucan compositions in mice and rats
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
BRIEF SUMMARY OF THE INVENTION
The present invention relates to a method for treating malignant tumors in mice and rats, and to a composition comprising a glucan in the form of an aqueous solution, and a composition comprising a glucan and known antitumor and/or anticancer agents which is useful as
Soluble phosphorylated glucan: methods and compositions for treatment of neoplastic diseases
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
TABLE OF CONTENTS
1. Field of the Invention
2. Background of the Invention
2.1. Immunobiological ctivity of Particulate Glucans
2.2. Adverse Side Effects of Particulate Glucans
2.3. Unsuccessful Attempts to Solubilize Particulate Glucans
3. Summary of the Invention
4. Brief Description of the
.beta.-glucan methods and compositions that affect the tumor microenvironment
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
BACKGROUND OF THE INVENTION
This disclosure relates to combinations of soluble .beta.-glucan and anti-cancer agents that affect the tumor microenvironment, including immunosuppression-relieving anti-cancer agents. .beta.-glucan is a fungal PAMP and is recognized by pattern recognition molecule C3 in
Beta-glucan in combination with anti-cancer agents affecting the tumor microenvironment
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
BACKGROUND OF THE INVENTION
The present invention relates to combinations of soluble .beta.-glucan and anti-cancer agents that affect the tumor microenvironment, including immunosuppression-relieving anti-cancer agents. .beta.-glucan is a fungal PAMP and is recognized by pattern recognition molecule
Cancer therapy using beta glucan and antibodies
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
BACKGROUND OF THE INVENTION
Beta(.beta.)-glucan is a complex carbohydrate, generally derived from several sources, including yeast, bacteria, fungi and cereal grains. Each type of .beta.-glucan has a unique structure in which glucose is linked together in different ways, resulting in different
Cancer therapy using beta glucan and antibodies
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
BACKGROUND OF THE INVENTION
Beta(.beta.)-glucan is a complex carbohydrate, generally derived from several sources, including yeast, bacteria, fungi and cereal grains. Each type of .beta.-glucan has a unique structure in which glucose is linked together in different ways, resulting in different
Radiolabeled glucans covalently linked to a radiolabel binding moiety
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to radiodiagnostic agents and reagents for preparing such agents, and also methods for producing radiolabeled radiodiagnostic agents. Specifically, the invention relates to technetium-99m (.sup.99m Tc) labeled agents,
Radiolabled glucans covalently linked to a radiometal binding moiety
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to radiodiagnostic agents and reagents for preparing such agents, and also methods for producing radiolabeled radiodiagnostic agents. Specifically, the invention relates to technetium-99m (.sup.99m Tc) labeled agents,
Radiolabeled glucans covalently linked to a radiolabel binding moiety
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to radiodiagnostic agents and reagents for preparing such agents, and also methods for producing radiolabeled radiodiagnostic agents. Specifically, the invention relates to technetium-99m (.sup.99m Tc) labeled agents,
Carboxymethylated derivatives of .beta.-1,3-glucan
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
This invention relates to a treatment of tumors and a new derivative of .beta.-1,3-glucan usable for the treatment.
For years there have been searches for substances which, with parenteral or oral administration, will cause the inhibition of tumor growth and the prolongation of the survival time of
Composition and method for treating cancer and immunological disorders resulting in chronic conditions
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
FIELD OF THE INVENTION
The present invention is directed to a composition for treating early stages of various forms of malignancies, particularly melanoma and lung cancer, in mammals. In more advanced stages of malignancies, such as those involving larger tumors and/or metastases, the composition
Soluble phosphorylated glucan
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
TABLE OF CONTENTS
1. Field of the Invention
2. Background of the Invention
2.1. Immunobiological Activity of Particulate Glucans
2.2. Adverse Side Effects of Particulate Glucans
2.3. Unsuccessful Attempts to Solubilize Particulate Glucans
3. Summary of the Invention
4. Brief Description of the
Soluble phosphorylated glucan
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
TABLE OF CONTENTS
1. Field of the Invention
2. Background of the Invention
2.1. Immunobiological Activity of Particulate Glucans
2.2. Adverse Side Effects of Particulate Glucans
2.3. Unsuccessful Attempts to Solubilize Particulate Glucans
3. Summary of the Invention
4. Brief Description of the
Therapy-enhancing glucan
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
Throughout this application, various references are cited. Disclosures of these publications in their entireties are hereby incorporated by reference into this application to more fully describe the state of the art to which this invention pertains.
BACKGROUND OF THE INVENTION
Beta-glucans have been
Baz done ki pi konplè remèd fèy medsin te apiye nan syans
- Travay nan 55 lang
- Geri èrbal te apiye nan syans
- Remèd fèy rekonesans pa imaj
- Kat entèaktif GPS - tag zèb sou kote (vini byento)
- Li piblikasyon syantifik ki gen rapò ak rechèch ou an
- Search remèd fèy medsin pa efè yo
- Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive
Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye
